Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > Online
COMMENTARY   Open Access     Cite

Paradigm shift in high-risk intrahepatic cholangiocarcinoma: Neoadjuvant GOLP and the dawn of precision perioperative oncology

  • 1.

    Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author: zhaoht@pumch.cn
  • Received Date:  March 13, 2026
    Accepted Date:  June 23, 2026
    Published Online:  June 24, 2026
The Innovation Medicine  https://doi.org/10.59717/j.xinn-med.2026.100249  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Shi G.M., Huang X.Y., Liang F., et al. (2026). Neoadjuvant GOLP in resectable high-risk intrahepatic cholangiocarcinoma. N. Engl. J. Med. 394:983−995. DOI:10.1056/NEJMoa2513918

    View in Article CrossRef Google Scholar

    [2] Primrose J.N., Fox R.P., Palmer D.H., et al. (2019). Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 20:663−673. DOI:10.1016/S1470-2045(18)30915-X

    View in Article CrossRef Google Scholar

    [3] Nakachi K., Ikeda M., Konishi M., et al. (2023). Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): A multicentre, open-label, randomised, controlled, phase 3 trial. Lancet 401:195−203. DOI:10.1016/S0140-6736(22)02038-4

    View in Article CrossRef Google Scholar

    [4] Goetze T.O., Vogel A., Pratschke J., et al. (2025). Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: Final results from the phase III AIO/CALGP/ACO-GAIN-Trial. J. Clin. Oncol. 43:4008−4008. DOI:10.1200/JCO.2025.43.16_suppl.4008

    View in Article CrossRef Google Scholar

    [5] Piao M., Li C., Li S., et al. (2026). Efficacy and safety of pembrolizumab, lenvatinib, and reduced-dose gemcitabine/oxaliplatin as initial treatment for advanced biliary tract cancer: A multicenter, single-arm, prospective, phase II study. J. Immunother. Cancer 14:e014653. DOI:10.1136/jitc-2025-014653

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Piao M. and Zhao H. (2026). Paradigm shift in high-risk intrahepatic cholangiocarcinoma: Neoadjuvant GOLP and the dawn of precision perioperative oncology. The Innovation Medicine 4:100249. https://doi.org/10.59717/j.xinn-med.2026.100249
    Piao M. and Zhao H. (2026). Paradigm shift in high-risk intrahepatic cholangiocarcinoma: Neoadjuvant GOLP and the dawn of precision perioperative oncology. The Innovation Medicine 4:100249. https://doi.org/10.59717/j.xinn-med.2026.100249

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
    Tables(1)

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(105) PDF downloads(80)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.